Camurus AB - Asset Resilience Ratio
Camurus AB (CAMX) has an Asset Resilience Ratio of 78.61% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read CAMX total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how Camurus AB's Asset Resilience Ratio has changed over time. See CAMX total equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Camurus AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Camurus AB stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr3.73 Billion | 78.61% |
| Short-term Investments | Skr0.00 | 0% |
| Total Liquid Assets | Skr3.73 Billion | 78.61% |
Asset Resilience Insights
- Very High Liquidity: Camurus AB maintains exceptional liquid asset reserves at 78.61% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Camurus AB Industry Peers by Asset Resilience Ratio
Compare Camurus AB's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 0.05% |
|
BrightGene Bio Medical Technology C
SHG:688166 |
Biotechnology | 1.00% |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233 |
Biotechnology | 0.02% |
|
Staidson Beijing Biopharma
SHE:300204 |
Biotechnology | 7.93% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 41.25% |
|
Ardelyx Inc
NASDAQ:ARDX |
Biotechnology | 41.14% |
|
Xiangxue Pharmaceutical
SHE:300147 |
Biotechnology | 0.05% |
Annual Asset Resilience Ratio for Camurus AB (2018–2025)
The table below shows the annual Asset Resilience Ratio data for Camurus AB.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 78.61% | Skr3.73 Billion ≈ $400.97 Million |
Skr4.74 Billion ≈ $510.10 Million |
+35.29pp |
| 2022-12-31 | 43.32% | Skr565.54 Million ≈ $60.86 Million |
Skr1.31 Billion ≈ $140.49 Million |
+5.28pp |
| 2021-12-31 | 38.04% | Skr411.57 Million ≈ $44.29 Million |
Skr1.08 Billion ≈ $116.43 Million |
-6.19pp |
| 2020-12-31 | 44.23% | Skr461.79 Million ≈ $49.70 Million |
Skr1.04 Billion ≈ $112.36 Million |
-2.24pp |
| 2019-12-31 | 46.47% | Skr358.74 Million ≈ $38.61 Million |
Skr772.05 Million ≈ $83.08 Million |
+9.62pp |
| 2018-12-31 | 36.84% | Skr134.38 Million ≈ $14.46 Million |
Skr364.72 Million ≈ $39.25 Million |
-- |
About Camurus AB
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029… Read more